Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 14;16(3):519-521.
doi: 10.5114/aoms.2020.94504. eCollection 2020.

Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2

Seyed Fazel Nabavi  1 , Solomon Habtemariam  2 , Emilio Clementi  3   4 , Ioana Berindan-Neagoe  5   6 , Cosmin Andrei Cismaru  5   7 , Mahsa Rasekhian  8 , Maciej Banach  9   10 , Morteza Izadi  1 , Mahdi Bagheri  1 , Mohammad Sadegh Bagheri  11 , Seyed Mohammad Nabavi  1
Affiliations

Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2

Seyed Fazel Nabavi et al. Arch Med Sci. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Abl kinase inhibition of early entry phases in the viral infectious cycle of SARS-CoV-2. Upon binding of SARS-CoV-2 spike protein to ACE2, the action of proteases at the cell membrane and in the endosomal compartment is required to complete the subsequent fusion steps of the virus. Abl kinase inhibitors act on proteases required for the completion of these steps by blocking their activity in SARS-CoV and MERS-CoV infection in vitro, and a similar activity of proteases is seen in SARS-CoV-2
See this image and copyright information in PMC

References

    1. Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020:105948. doi: 10.1016/j.ijantimicag.2020.105948. - DOI - PMC - PubMed
    1. World Health Organization Coronavirus disease 2019 (COVID-19): situation report. 2020;83
    1. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20:398–400. - PMC - PubMed
    1. Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400–2. - PMC - PubMed
    1. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020 doi: 10.1056/NEJMoa2001282. - DOI - PMC - PubMed